Latest Intelligence on Pharmaceutical Contract Research Organizations in Europe

Published within

« | 1 | 2 | 3 | 4 | » »|

Type Product title / description Pub Price
Expert View
Expert View

ASH 2009: competition between Velcade and Revlimid intensifies in multiple myeloma

Datamonitor attended this year's American Society of Hematology annual meeting in New Orleans, focusing on key developments in hematological malignancies. While recent trial results are likely to support new applications for Velcade and Revlimid in first-line multiple myeloma, the data also suggest that the future of treatment may actually be a combination of the two.

Published By Datamonitor
11 Dec 2009
Expert View
Expert View

ASH 2009: Novartis looks to position Tasigna as an alternative to Gleevec in CML

At this year's American Society of Hematology meeting, researchers presented results from a Phase III study comparing Tasigna and Gleevec in newly diagnosed chronic myeloid leukemia. While Tasigna's efficacy is impressive, it is unlikely that the drug will achieve the same market penetration as Gleevec in newly diagnosed patients due to fierce competition from Sprycel.

Published By Datamonitor
11 Dec 2009
CommentWire
CommentWire

Genentech/Biogen Idec: ocrelizumab encouraging in trials but lacks differentiation

Partners Genentech and Biogen Idec have announced positive results from the Phase III STAGE trial of ocrelizumab in rheumatoid arthritis. The positive data come as no real surprise and Datamonitor expects that ocrelizumab will launch for rheumatoid arthritis. However, the drug will suffer from a lack of differentiation from other B cell therapies.

Published By Datamonitor
11 Dec 2009
CommentWire
CommentWire

Concert: protease inhibitor holds potential to be prescribed un-boosted

US healthcare firm Concert Pharmaceuticals has initiated a Phase Ib study for its protease inhibitor CTP-518. Early data on the candidate suggest that, unlike many marketed protease inhibitors, it does not require ritonavir boosting. Datamonitor believes that if these results are confirmed in larger studies, the compound has a strong chance of gaining commercial success.

Published By Datamonitor
10 Nov 2009
CommentWire
CommentWire

Noven: Mesafem emerges as potential alternative to HRT

Recently announced results suggest that Noven's non-hormonal therapy Mesafem is effective in relieving vasomotor symptoms associated with the menopause. However, Datamonitor believes that Mesafem will have to demonstrate equivalent or superior efficacy to hormonal replacement therapy if it is to overcome the challenges in this underserved market.

Published By Datamonitor
17 Jul 2009
CommentWire
CommentWire

Pfizer: development setbacks cast doubt over Sutent

For the third time in 2009, Pfizer has terminated a Phase III study of Sutent, this time in metastatic colorectal cancer. Although the drug remains likely to achieve blockbuster sales within its existing approved indications, this latest setback casts further doubt over its clinical potential in larger, more lucrative indications.

Published By Datamonitor
02 Jul 2009
CommentWire
CommentWire

Jazz Pharmaceuticals/UCB: fibromyalgia beckons for narcolepsy drug

New positive top-line results from a second Phase III clinical trial of sodium oxybate in fibromyalgia show that the drug is on track for FDA approval. As such, the treatment is set to enter the market as the fourth drug to be approved for fibromyalgia in the US. Despite impressive efficacy data, however, prescriptions are likely to be limited by accessibility, price and convenience.

Published By Datamonitor
26 Jun 2009
CommentWire
CommentWire

Cell Therapeutics: pixantrone close to extending lymphoma treatment options

Having reported positive follow-up results for pixantrone from the pivotal Phase III EXTEND trial, Cell Therapeutics has now submitted a marketing application with the FDA for the drug in relapsed/refractory, aggressive non-Hodgkin's lymphoma. Pixantrone's chance of approval looks promising as it addresses an important unmet need for more effective third-line therapies in this population.

Published By Datamonitor
24 Jun 2009
Expert View
Expert View

DDW 2009: the anti-TNF battle

Datamonitor attended this year's Digestive Disease Week (DDW) in Chicago, the world's largest gathering of physicians, researchers and opinion leaders in the field of digestive diseases. An ongoing theme of debate at DDW was the timing of biologic therapy introduction in inflammatory bowel diseases, and the efficacy of combination therapy with TNF inhibitors.

Published By Datamonitor
15 Jun 2009
Expert View
Expert View

DDW 2009: Clostridium difficile-associated colitis

A disease that is gaining more importance both in terms of incidence rates and virulence is Clostridium-difficile-associated colitis. Recurrence rates remain high and an emerging strain has proven to be responsible for an increasing number of outbreaks. At Digestive Disease Week 2009, two companies presented promising updates of their respective programs, both with very different approaches.

Published By Datamonitor
15 Jun 2009

« | 1 | 2 | 3 | 4 | » »|

No help is available.